[Report] Antidyslipidemics Commercial Insight Market Research, Trends, Analysis TOC

About the Cardiovascular pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
- Datamonitor insight into the dyslipidemia market
CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Market definition for this report
- Current market situation
- National markets
- The statin market
  - Lipitor - the global market leader
  - Crestor - fastest-growing statin
- Combination therapy
  - Vytorin
- The fibrate market
  - TriCor/Lypanthyl (fenofibrate)
- The cholesterol uptake inhibitor market
  - Zetia
- The nicotinic acid derivatives
  - Niaspan
- The ion exchange resins
- The other antidyslipidemics market
  - Omega-3 oils
  - Probucol, Benflourex and Colesevelam
CHAPTER 3 COUNTRY MARKET ASSESSMENTS
- Current and future opportunities and threats in the antidyslipidemic market
  - Global opportunities and threats
    - Opportunities
  - Threats
    - Patent expiry and generic erosion
- US: opportunities and threats
  - Market overview
    - Opportunities
    - Threats
- Japan: opportunities and threats
  - Market overview
    - Opportunities
    - Threats
- France: opportunities and threats
  - Market overview
    - Opportunities
    - Threats
- Germany: opportunities and threats
  - Market overview
    - Opportunities
    - Threats
- Italy: opportunities and threats
  - Market overview
    - Opportunities
    - Threats
- Spain: opportunities and threats
  - Market overview
    - Opportunities
    - Threats
- UK: opportunities and threats
  - Market overview
    - Opportunities
    - Threats
- Summary of environmental issues affecting the antidyslipidemic market size
CHAPTER 4 FORECAST ANALYSIS
- Assumptions and events
  - Trial results
    - ASCOT
    - INTER HEART
- New product launches
  - Atorvastatin + torcetrapib
  - Livalo
- Forecasts
CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES
- Pfizer's franchise rotation strategies: a means of protecting brand revenue
  - Lipitor: Pfizer's biggest success
  - Lipitor: sales are forecast to plummet in the next decade
  - Atorvastatin + torcetrapib: will this FDC be Pfizer's next blockbuster?
  - Caduet (atorvastatin + amlodipine): a winning combination?
- Implications of two recent trials
  - IDEAL TRIAL: implications
  - Japanese MEGA trial
APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS
- Statin market data
  - Lipitor
  - Zocor
  - Pravachol
  - Crestor
  - Vytorin
- Fibrate market data
  - Lipanthyl/Tricor
  - Cedur/Bezatol
- Cholesterol uptake inhibitors
  - Zetia
- Nicotinic acid derivatives
  - Niaspan
- Ion exchange resins
  - Questran
- Other antidyslipidemics
  - WelChol
APPENDIX B
- Bibliography
  - Epidemiology
  - Clinical trial data
  - Datamonitor
  - Other research articles
  - Press releases
  - Websites
- Report methodology
  - Japan sales data
  - Key opinion leaders
APPENDIX C - MARKET FORECAST DATA
- US forecasts
- Japan forecasts
- France forecasts
- Germany forecasts
- Italy forecasts
- Spain forecasts
- UK forecasts
- M5EU forecasts
- Global forecasts
- About Datamonitor
  - About Datamonitor Healthcare
  - About the Cardiovascular analysis team
- Disclaimer
- List of Tables
  - Table 1: Key players in the antidyslipidemic market
  - Table 2: Global sales of the antidyslipidemic drug classes, 2004
  - Table 3: Global sales of the branded and generic statins, 2004
  - Table 4: Global sales of the branded and generic fibrates, 2004
  - Table 5: Sales of Zetia in each market, 2004
  - Table 6: Global sales the nicotinic acid derivatives, 2004
  - Table 7: Global sales of the ion exchange resins, 2004
  - Table 8: Global sales of omega-3 oils, 2004
  - Table 9: Global combined Sales of Probucol, Benflourex and Colesevelam, 2004
  - Table 10: US antidyslipidemic market data, 2004
  - Table 11: Japan antidyslipidemic market data
  - Table 12: France antidyslipidemic market data
  - Table 13: Germany antidyslipidemic market data
  - Table 14: Italy antidyslipidemic market data
  - Table 15: Drivers and resistors for genericization in the Italian pharmaceutical market
  - Table 16: Spain antidyslipidemic market data
  - Table 17: UK antidyslipidemic market
  - Table 18: Year of patent expiries of major brands
  - Table 19: Lipitor: key facts
  - Table 20: Zocor: key facts
  - Table 21: Pravachol: key facts
  - Table 22: Crestor: key facts
  - Table 23: Vytorin: key facts
  - Table 24: Lipanthyl/Tricor: key facts
  - Table 25: Cedur/Bezatol: key facts
  - Table 26: Zetia: key facts
  - Table 27: Niaspan: key facts
  - Table 28: Questran: key facts
  - Table 29: WelChol: key facts
  - Table 30: US forecasts to 2014, in $ millions
  - Table 31: Japan forecasts to 2014, in $ millions
  - Table 32: France forecasts to 2014, in $ millions
  - Table 33: Germany forecasts to 2014, in $ millions
  - Table 34: Italy forecasts to 2014, in $ millions
  - Table 35: Spain forecasts to 2014, in $ millions
  - Table 36: UK forecasts to 2014, in $ millions
  - Table 37: EU markets forecasts to 2014, in $ millions
  - Table 38: Global forecasts to 2014, in $ millions
- List of Figures
  - Figure 1: Share of the antidyslipidemic market represented by each of the seven major markets 2004
  - Figure 2: Global sales of the antidyslipidemic drug classes
  - Figure 3: Proportion of overall drug-treated dyslipidemia patients receiving combination therapy in the seven major markets, 2005
  - Figure 4: Percentage of the population over 65 in 2005 (value shown) and a forecast for the next and 10 and 20 years.
  - Figure 5: Percentage of men and women over the age of 45 & 55 respectively, in the general population.
  - Figure 6: Annual US sales of the antidyslipidemic drug classes
  - Figure 7: Annual US sales of the drug classes excluding the statins
  - Figure 8: 2004 sales of the statin brands in Japan
  - Figure 9: Annual Japanese sales of the antidyslipidemic classes
  - Figure 10: Contribution of the three key sources to the Japanese healthcare system, 2001
  - Figure 11: Annual French sales of the antidyslipidemic drug classes
  - Figure 12: Antidyslipidemics sales in Germany ($m), including statins, 2001-04
  - Figure 13: Antidyslipidemics sales in Germany ($m), excluding statins, 2001-04
  - Figure 14: Annual Italian sales of the antidyslipidemic drug classes
  - Figure 15: Annual sales of the antidyslipidemic classes
  - Figure 16: Annual Spanish sales of the antidyslipidemic drug classes excluding the statins
  - Figure 17: Annual sales of the antidyslipidemic drug classes
  - Figure 18: Annual sales of the antidyslipidemic drug classes
  - Figure 19: Summary of environmental issues

Commercial Insight: Antidyslipidemics - Statins Hit the Brakes on Market Growth

Table of Contents